Sign In
Buy SNY
$42.37
-0.430 (-1.00%)
At Close: Jun 03, 2026
Kali Therapeutics signs deal with Sanofi to develop autoimmune treatment
07:57am, Monday, 23'rd Mar 2026
Kali Therapeutics said on Monday it has entered into a licensing agreement with French drugmaker Sanofi to develop the privately held firm's experimental treatment for several autoimmune disease
Sanofi launches innovation and operation centre in China
10:58am, Friday, 20'th Mar 2026
French drugmaker Sanofi launched an innovation and operation centre in the southwestern Chinese city of Chengdu on Thursday, the company said in a statement released on its Chi
TrumpRx lists many medicines at prices higher than paid in UK
02:23pm, Wednesday, 18'th Mar 2026
U.S. President Donald Trump pledged to make prescription drugs cheaper for Americans than anywhere in the world, but his TrumpRx.gov website is not delivering across the board lower prices than those
20 Years on Wall Street Taught Me: Big Dividend Healthcare Stocks Never Go Out of Style
07:19am, Wednesday, 18'th Mar 2026
After a career spanning two decades at Bear Stearns, Lehman Brothers, and Morgan Stanley, I gained an institutional perspective on dividend stock investing.
Mirecule Expands Strategic FSHD Collaboration with Sanofi
07:00am, Wednesday, 18'th Mar 2026
GAITHERSBURG, Md.--(BUSINESS WIRE)--Mirecule expands strategic collaboration with Sanofi on advancement of best-in-class ARC treatment of Facioscapulohumeral Muscular Dystrophy (FSHD).
Press Release: Sanofi's venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease
02:00am, Wednesday, 18'th Mar 2026
Sanofi's venglusta t earns Breakthrough Therapy designation in the US for type 3 Gaucher disease Paris, March 18, 2026 . The US Food and Drug Administration (FDA) has granted Breakthrough Therap
Big drugmakers must face US overcharge claims on medications for low-income patients
02:32pm, Tuesday, 17'th Mar 2026
A U.S. appeals court on Tuesday revived a whistleblower lawsuit accusing four large drugmakers of defrauding the federal and state governments out of hundreds of millions of dollars by overcharg
The Big 3: PR, ELF, SNY
01:27pm, Tuesday, 17'th Mar 2026
From oil, beauty, and therapeutic resource stocks, @ElliottWaveTrader's Tammy Marshall turns to three companies she sees as unsung market opportunities. The Fibonacci Princess offers insight and
Sanofi: An Undervalued Stock For Long-Term Dividend Growth Investors
11:03am, Monday, 16'th Mar 2026
Sanofi has increased its dividend for 31 consecutive years. That's a fantastic track record. Sanofi increased its revenue from €34.7 billion in FY 2016 to €43.6 billion in FY 2025. That's a compo
Callodine Capital Management LP Purchases 182,837 Shares of Sanofi $SNY
03:48am, Saturday, 14'th Mar 2026
Callodine Capital Management LP grew its stake in Sanofi (NASDAQ: SNY) by 35.5% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The
Sanofi: Information concerning the total number of voting rights and shares - February 2026
01:30pm, Thursday, 12'th Mar 2026
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement
Brazil drugmaker EMS eyes overseas deals after buying Sanofi unit
04:16pm, Tuesday, 10'th Mar 2026
Brazilian drugmaker EMS is open to fresh acquisitions to expand internationally after inking a major deal to buy Sanofi's Brazil-based generic drugmaker Medley, and is gearing up to launch its own
Sanofi (NASDAQ:SNY) Hits New 1-Year Low – Here’s Why
01:32am, Sunday, 08'th Mar 2026
Sanofi (NASDAQ: SNY - Get Free Report) shares hit a new 52-week low during mid-day trading on Friday. The company traded as low as $44.01 and last traded at $44.01, with a volume of 93153 shares. The
Need Growing EPS And Dividends? Prescribe Sanofi
08:00am, Friday, 06'th Mar 2026
Sanofi is deeply undervalued, trading at a 29% discount to a $65 fair value estimate, with a forward P/E of 9.2 versus a 10-year average of 13. Robust growth is driven by blockbuster drugs like Dupixe
Press Release: Sanofi's Board of Directors proposes the appointment of Christel Heydemann as an independent director
03:16am, Thursday, 05'th Mar 2026
Sanofi's Board of Directors proposes the appointment of Christel Heydemann as an independent director
